InMode Ltd. (NASDAQ:INMD) Stock Has Consensus Target Price of $16.00 According to Analysts

Key Points

• Analysts maintain a “Hold” consensus on InMode, with four hold, one sell, and one buy rating among six firms. The average 12-month price target is $16.00, compared with a recent share price of $13.51.
• InMode’s latest quarterly results met expectations, with EPS of $0.35 and revenue of $95.59 million versus the $94.89 million estimate. Net margin was 20.69% and return on equity was 11.99%.
• Institutional investors own approximately 68.04% of InMode’s stock, while several funds recently increased their positions. The stock has traded between $12.72 and $16.67 over the past year.

Shares of InMode Ltd. (NASDAQ:INMD - Get Free Report) have received a consensus recommendation of "Hold" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $16.00.

Separately, Weiss Ratings reiterated a "sell (d+)" rating on shares of InMode in a report on Thursday, August 6th.

InMode Stock Up 1.0%

Shares of INMD opened at $13.51 on Friday. InMode has a 12-month low of $12.72 and a 12-month high of $16.67. The business has a 50-day simple moving average of $14.41 and a two-hundred day simple moving average of $14.33. The stock has a market cap of $776.55 million, a PE ratio of 10.98 and a beta of 2.03.

InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The healthcare company reported $0.35 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.35. The firm had revenue of $95.59 million during the quarter, compared to analysts' expectations of $94.89 million. InMode had a net margin of 20.69% and a return on equity of 11.99%. The company's revenue was up .0% on a year-over-year basis. During the same period in the prior year, the company posted $0.47 EPS.

Institutional Investors Weigh In On InMode

Several institutional investors and hedge funds have recently made changes to their positions in the business. Inspire Investing LLC grew its stake in InMode by 6.1% during the first quarter. Inspire Investing LLC now owns 19,366 shares of the healthcare company's stock worth $265,000 after purchasing an additional 1,111 shares during the period. Plan A Wealth LLC lifted its stake in InMode by 8.4% in the third quarter. Plan A Wealth LLC now owns 19,201 shares of the healthcare company's stock valued at $272,000 after buying an additional 1,481 shares during the period. Evergreen Capital Management LLC lifted its stake in InMode by 10.8% in the third quarter. Evergreen Capital Management LLC now owns 15,606 shares of the healthcare company's stock valued at $221,000 after buying an additional 1,519 shares during the period. IFP Advisors Inc bought a new position in shares of InMode during the 2nd quarter worth approximately $31,000. Finally, Blue Trust Inc. boosted its holdings in shares of InMode by 69.4% during the 1st quarter. Blue Trust Inc. now owns 5,567 shares of the healthcare company's stock worth $76,000 after buying an additional 2,281 shares in the last quarter. Institutional investors own 68.04% of the company's stock.

About InMode

InMode Ltd. NASDAQ: INMD is a global medical technology company that develops and commercializes energy-based platforms for aesthetic and medical treatments. Its systems are designed to support minimally invasive and noninvasive procedures performed by physicians and other healthcare professionals.

The company's product portfolio includes platforms and handpieces used in facial and body contouring, skin resurfacing, skin tightening, hair removal, and women's health applications. Its technologies include radio-frequency and other energy-based treatments, with products such as Morpheus8, BodyTite, FaceTite, Optimas, and EmpowerRF serving a range of clinical and aesthetic needs.

Founded in 2008, InMode sells its products through direct sales and distribution channels to medical practices, clinics, and other healthcare providers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.